DESIGNED FOR PURPOSE.

BUILT FOR COLD.

Who is phasetwo?

phasetwo® offers a full range of storage products that have been re-engineered with a user-centric focus, rather than legacy and outdated designs.

Our next generation solutions serve the Life Science sectors including Biotech, Cell and Gene Therapy, Dermatology, Biobanking, In Vitro Fertilization and more.

Our advanced cold storage products include Cryogenic Storage Stainless Steel Freezers, Cryogenic Aluminum Freezers, Cryogenic Control Rate Freezers, Cryogenic Blast Freezers, and Dry Ice Equipment.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Vapor Shippers (Dry Shippers)

    Read more

    Shipping Case

    Dewar Series

    Read more

    Liquid Withdrawal Device (LWD)

    High Capacity High Efficiency Freezers

    Read more

    Long-Term Freezers

    Read more

    Cryogenic Canister Freezers

    Read more

    Cryogenic Rack Freezers

    Read more

    Low Level & Temperature Alarm (LLTA)

    Go to article: Home | What’s next for AAV gene therapies in 2024?Go to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: phasetwoGo to article: Avenga Company InsightGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: Zenatek Company InsightGo to article: Simtra BioPharma SolutionsGo to article: In DepthGo to article: What’s Next for AAV Gene Therapies in 2024?Go to article: Traceability technologies tighten supply chain fakeryGo to article: Switching sales: Investigating the financial impacts of FDA’s priority vouchersGo to article: Is HIV-TB coinfection treatment entering a new frontier?Go to article: Patient organisations need to tackle transparency Go to article: AD/PD 2024: Eli Lilly’s donanemab hit with FDA delay Go to article: Q&A: Increasing awareness around digital therapeutics key to realising full potentialGo to article: Sponsored SupplementsGo to article: Lactalis IngredientsGo to article: BEA TechnologiesGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue